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Background: In this clinical trial we compared the effects of broccoli sprouts powder, as an alternative and
complementary treatment, to those of standard triple therapy, as a common medical treatment, on cardiovascular
risk factors following the H.pylori eradication in patients with type 2 diabetes.
Methods: Eighty-six type 2 diabetic patients with positive H.pylori stool antigen test (HpSAg) were randomized to
receive one of the three following regimens: STT) Standard triple therapy (omeprazole 20 mg, clarithromycin
500 mg, amoxicillin 1000 mg, twice a day for 14 days), BSP) 6 g/d broccoli sprouts powder for 28 days, and
combination of these as STT + BSP. After 4 weeks of treatment, H.pylori eradication rates were assessed by HpSAg.
Anthropometric measures, blood pressure, serum lipids and lipoproteins as well as serum high sensitive- C reactive
protein were also assessed at baseline and at the second examination.
Results: Seventy-seven participants completed the study [STT (n = 28), BSP (n = 25), STT + BSP (n = 24)]. The H.pylori
eradication rates were 89.3%, 56.0% and 91.7% in STT, BSP and STT + BSP groups, respectively. After the treatment,
both systolic and diastolic blood pressure significantly decreased in STT + BSP group (P < 0.05). Serum triglycerides
and TG/HDL-C ratio increased in STT patients group (<0.05). Serum hs-CRP levels significantly decreased in the
patients who were treated with BSP per se (3.0 ± 2.5 at baseline vs. 2.3 ± 2.1 after the treatment, P < 0.05).
Conclusion: Compared to standard triple therapy, BSP regimen in addition to considerable effects on H.pylori
eradication had also favorable properties on cardiovascular risk factors following the H.pylori eradication.
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Cardiovascular risk factorIntroduction
Current data suggest that patients with type 2 diabetes
are more prone to some infectious diseases including
helicobacter pylori infection, with a higher prevalence of
this infection has been reported in diabetes patients as
compared to non-diabetes [1,2]. In fact, there is a* Correspondence: azizi@endocrine.ac.ir
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unless otherwise stated.bilateral relation between H.pylori infection and type 2
diabetes and this infection is proposed as a major
contributing factor for development of insulin resistance,
sub-clinical inflammation, long-term diabetes complications
and cardiovascular risk factors [3-5]. Patients with diabetes
are also more resistant to common treatments of H.pylori
infection and the risk of re-infection in these patients
is higher in the non-diabetes subjects [3,6]. On the
other hand, since undesirable side effects may occur
during treatment with common anti H.pylori regimens
which could affect diabetes management it is moreal Ltd. This is an Open Access article distributed under the terms of the Creative
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H.pylori eradication, with high efficacy, and low risk of
recurrent and side effects in patients with type 2 diabetes
compared to others. The use of natural antibacterial agents
including phytochemicals and bioactive nutraceuticals
for H.pylori eradication is currently considered as a
new approach with more effectiveness and safer outcomes
[7-9]. Broccoli sprouts due to its high content of sulforaph-
ane (SFN), a most potent bactericidal agent, is recently
being considered for treatment of H.pylori infection and
related disorders [10-12].
In the current study we aimed to compare the effects
of broccoli sprouts powder, as both alternative and
complementary treatments, with standard triple therapy
(omeprazole + clarithromycin + amoxicillin), as a common
medical treatment, on cardiovascular risk factors following
the H.pylori eradication in patients with type 2 diabetes.
Methods
Study population
In this randomized clinical trial men and women, aged
25–60 years, with a clinical diagnosis of type 2 diabetes
for at least one year, who referred to Iran Diabetes Society
and endocrinology clinic of Taleghani Medical Center
were recruited. The purpose and protocol of the study
were explained for the patients. Exclusion criteria were
including: previous treatment of H.pylori, consumption of
PPIs, H2 receptor antagonists, bismuth compounds or
antibiotics during the last month, previous gastric surgery,
severe illness, gestation or lactation, estrogen therapy, take
of vitamin K-antagonists or antioxidant supplements. Two
hundred eighty-four patients with type 2 diabetes were
eligible to participants in the study, of those 93 patients
refused to participants and 191 patients were assessed for
H.pylori infection.
Ethical committee of the Research Institute for Endocrine
Sciences of the Shahid Beheshti University of Medical
Sciences approved this clinical trial and informed written
consents were obtained from all participants. The trial
was registered with the following identification: IRCT
201111081640N6. The results are reported according to
Consolidated Standards of Reporting Trials guidelines 2010.
H.pylori detection, randomization, and intervention
To detect H.pylori infection, stool samples were obtained
from all participants. Then samples were tested by
stool antigen test (HpSAg) ELISA kits, according to the
manufacturers' instructions. Participants were considered
as positive H.pylori infection if HpSAg ≥ 0.055 μg/ml
(n =108), borderline if 0.045 ≤HpSAg < 0.055 μg/ml
(n = 10) and negative if HpSAg < 0.045 μg/ml (n = 73).
It should be noted that the H.pylori positive patients
had no sever gastrointestinal complications and did not
require to urgent classic treatment for the infection.Twenty-two patients with positive H.pylori test did not
participants in treatment and the rest were assigned
randomly into 3 groups: A) STT: Standard triple therapy
including omeprazole 20 mg, clarithromycin 500 mg,
amoxicillin 1000 mg, twice a day for 14 days (n = 33); B)
BSP: 6 g/d broccoli sprouts powder for 28 days (n = 28);
C) STT + BSP: standard triple therapy for 14 days plus
6 g/d broccoli sprouts powder for 28 days (n = 25).
Stratified randomization was performed using sealed
envelopes for group allocation. Broccoli sprouts powder
contain at least 22.5 μmol standardized for sulforaphane
per each gram, was purchased from the Cyvex Nutrition
Company (CA, USA). To evaluate compliance to inter-
vention and to enquire regarding any possible side
effects we contacted participants weekly. One month
after treatment, stool samples were obtained again to
assess H.pylori eradication rates. After the intervention,
all the patients in the BSP groups who remained H.pylori
positive received standard triple therapy.
Demographics, anthropometrics and clinical
measurement
Data on age, educational level, medical history and
medications, duration of diabetes and oral anti-diabetes
drugs, were collected at baseline by trained interviewers
using pretested questionnaires.
Anthropometric indices were measured at baseline
and one month after treatment, by trained staff. Weight
was measured to the nearest 100 g with minimum cloths,
without shoes, using digital scale. Height was measured to
the nearest 0.5 cm, using a tape meter while the partici-
pants were in a standing position without shoes. Waist
circumference (WC) were measured to the nearest 0.1 cm
(at anatomical landmarks), at the widest portion, without
any pressure to the body using a non-stretched tape meter.
Body mass index (BMI) was calculated as weight (kg)
divided by square of the height (m2).
Blood pressure (BP) measured twice, on the right
arm, after a 15-minute rest in the sitting position,
using a standardized mercury sphygmomanometer. The
mean of the two measurements was considered as the
participant's BP.
Biochemical measurement
Venous blood samples were obtained after 12-h fasting
at baseline and 1-month after treatment and stored
at the laboratory of Research Institute for Endocrine
Science until assay. Fasting serum glucose, total cholesterol
and triglycerides was measured by the enzymatic colori-
metric method using kits (Pars Azmoon Company, Tehran,
Iran). High density lipoprotein cholesterol was measured
after precipitation of apo B containing lipoproteins with
phosphotungstic acid using kit (Pars Azmoon Company,
Tehran, Iran). LDL-C was calculated according to the
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was measured using the enzyme-linked immunosorbent
assay (ELISA) kit (Diagnostics Biochem Canada Inc.,
Ontario, Canada). Inter- and Intra-assay coefficients
of variation of all assays were < 5%. Atherogenic lipid
and lipoprotein ratio including TG/HDL, TC/HDL
and LDL/HDL ratio were calculated at baseline and
1-month after treatment.
Statistical methods
The sample size was designed to detect a 0.05 μg/ml
difference among groups in H.pylori stool antigen with
95% CI and 90% power, and with regard to the possible loss
of samples was calculated for 25 patients in each group. All
statistical analyses were conducted on the intention-to-treat
principle and included all negative HpSAg participants at
the follow-up. The Kolmogorov-Smirnov test was used to
test for a normal distribution. To compare the means
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Figure 1 Flow chart of the study.Kruskal-Wallis test were used. To compare baseline and
after treatment-values in each group paired t-test or
Mann–Whitney test were used. The general linear model
(ANCOVA) was used to compare means of the variables
after treatment and obtain the main effect of each regimen
(STT, BSP, STT+ BSP). When the analysis indicated a
significant effect of treatment, the groups were compared
pair-wise by the Bonferroni. All Statistical analyses were
performed using SPSS (version 16.0; SPSS, Inc., Chicago,
IL, USA). A P value < 0.05 was considered significant.
Results
Of eighty-six randomized patients, seventy-seven completed
the study [STT (n = 28), BSP (n = 25), STT + BSP (n = 24)]
Figure 1; the mean age, weight and waist circumference of
participants was 51 ± 13 years, 81 ± 14 kg and 100 ± 11 cm,
respectively. Forty-five percent of the participants were
men. Sixty-eight (88.3%) patients with type 2 diabetes were
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There were no significant differences between the three
groups in medications, including anti-diabetes drugs, lipid
lowering or antihypertensive drugs.
Mean fasting glucose levels at baseline were 164 ± 59,
154 ± 46, and 157 ± 51 mg/dl in groups A, B and C,
respectively. Mean HpSAg levels at baseline were
similar in the three groups (0.29 ± 0.25, 0.24 ± 0.20,
and 0.25 ± 0.23 in the group A, B and C, respectively). No
significant differences between the groups were observed at
baseline examination for age, weight, waist circumference,
systolic and diastolic blood pressure, duration of diabetes,
and biochemical measurements. The most common
adverse events observed during the intervention were
diarrhea (9.6%) and nausea (3.8%) in patients who received
standard triple therapy.
The eradication rates of H.pylori, assessed by HpSAg,
were 89.3%, 56.0%, and 91.7% in the STT, BSP, and STT+
BSP groups, respectively. Final analyses were conducted on
all participants with negative HpSAg at the follow-up.
Baseline and post-treatment anthropometrics as well as
cardiovascular risk factors in patients with successfully
eradicated H.pylori in the three groups are compared in
Table 1. After the treatment, both systolic and diastolic
blood pressure significantly decreased in patients who were
treated with standard triple therapy plus broccoli sprouts
powder (P < 0.05). Serum total cholesterol moderately but
non-significantly increased in the STT and STT + BSP
groups, and remained unchanged in the BSP group. As
compared to baseline, serum triglycerides significantly
increased in the STTgroup (154 ± 109 vs. 131 ± 80, P< 0.05);
triglycerides to HDL-C ratio, a main atherogenic index of
plasma, also increased in patients treated with STTTable 1 Baseline and after treatment values in successful H.p
Standard triple therapy
(n = 25)
Baseline After treatment Ba
Weight (kg) 83.3 ± 15.8 82.5 ± 16.4 75
Waist circumference (cm) 104 ± 10.7 102 ± 13.2 94
Systolic blood pressure (mmHg) 130 ± 20 125 ± 11 12
Diastolic blood pressure (mmHg) 80.4 ± 16.2 79.4 ± 8.6 80
Total cholesterol (mg/dl) 158 ± 38 166 ± 40 15
Triglycerides (mg/dl) 131 ± 80 154 ± 109a 10
HDL-cholesterol (mg/dl) 30.1 ± 4.0 29.0 ± 3.4 29
LDL-cholesterol (mg/dl) 104 ± 29 108 ± 30 11
Triglycerides/HDL-C 4.5 ± 2.9 5.5 ± 3.9a 3
Total cholesterol/HDL-C 5.6 ± 1.6 5.8 ± 1.6 5
LDL-C/HDL-C 3.5 ± 0.9 3.8 ± 1.1 3
hs-CRP (mg/l) 3.3 ± 2.5 3.1 ± 2.4 3
All values are mean ± SD.
There was no significant difference in the clinical variables between the three grou
aSignificantly different from baseline values (student paired t-test was used) p < 0.05per se (4.5 ± 2.9 at baseline vs. 5.5 ± 3.9 after the treatment,
P < 0.05); no significant changes in LDL-C and HDL-C
levels of the 3 groups were observed. Serum hs-CRP levels
after the treatment significantly decreased in patients
treated with BSP per se (3.0 ± 2.5 at baseline vs. 2.3 ± 2.1
after the treatment, P < 0.05), and remained unchanged in
other groups. When, after treatment values adjusted for
baseline levels were compared between the three groups,
triglyceride levels were significantly higher in STT
group as compared with others, and treatment effects
of STT on increased levels of triglycerides was significant
(P for treatment effect <0.05). The TG/HDL-C ratio in the
three groups ranked as follows: STT > STT + BSP > BSP;
differences however not statistically significant. Serum
level of hs-CRP in the BSP group was non-significantly
lower than the STT + BSP and STT groups, respectively
Table 2.
Discussion
The results of this clinical trial showed that compared to
the common standard triple therapy, broccoli sprouts
powder in addition to its considerable effect on H.pylori
eradication, could also have favorable effects on cardio-
vascular risk factors following the treatment.
The possible synergistic hypotensive effect of broccoli
sprouts powder and standard triple therapy was an
important finding observed following H.pylori eradication
in this study; a moderate decrease of systolic and diastolic
blood pressure was however observed in all patients with
successfully eradicated H.pylori, this decrease was as
follows BSP + STT> BSP > STT, and was only significant in
BSP + STT treatment group. The association between H.
pylori infection and elevated blood pressure is controversialylori eradicated patients in the three groups
Broccoli sprouts powder
(n = 14)
Standard triple therapy + Broccoli
sprouts powder (n = 22)
seline After treatment Baseline After treatment
.7 ± 16.1 75.3 ± 15.8 73.8 ± 10.7 72.8 ± 10.5
.8 ± 14.7 95.5 ± 12.4 94.1 ± 8.3 92.6 ± 8.6
5 ± 20 119 ± 24 136 ± 23 122 ± 14a
.4 ± 12.4 76.8 ± 16.8 89.8 ± 16.2 80.4 ± 10.4a
7 ± 32 156 ± 11 152 ± 31 165 ± 33
7 ± 50 110 ± 51 113 ± 88 114 ± 55
.3 ± 2.6 28.7 ± 2.1 30.1 ± 3.6 29.1 ± 2.6
1 ± 27 108 ± 31 106 ± 28 114 ± 26
.8 ± 1.9 3.9 ± 1.9 3.9 ± 2.7 4.0 ± 2.1
.5 ± 1.5 5.4 ± 1.5 5.6 ± 1.4 5.7 ± 1.3
.8 ± 1.2 3.8 ± 1.1 3.6 ± 1.2 4.0 ± 1.1
.0 ± 2.5 2.3 ± 2.1a 2.4 ± 1.9 2.5 ± 2.3
ps (analysis of variance was used).
.




powder (n = 14)
Standard triple therapy + Broccoli
sprouts powder (n = 22)
p for treatment
effecta
Systolic blood pressure (mmHg) 126 ± 4 122 ± 5 120 ± 4 0.63
Diastolic blood pressure (mmHg) 81 ± 3 78 ± 3 77 ± 3 0.68
Total cholesterol (mg/dl) 166 ± 8 156 ± 13 166 ± 8 0.82
Triglycerides (mg/dl) 154 ± 14 99 ± 29b 118 ± 15b 0.05
HDL-cholesterol (mg/dl) 29.0 ± 0.6 28.7 ± 1.1 29.0 ± 0.7 0.96
LDL-cholesterol (mg/dl) 108 ± 6 108 ± 10 114 ± 7 0.76
Triglycerides/HDL-C 5.5 ± 0.6 3.4 ± 1.1 4.2 ± 0.7 0.08
Total cholesterol/HDL-C 5.8 ± 0.3 5.5 ± 0.5 5.7 ± 0.3 0.88
LDL-C/HDL-C 3.8 ± 0.2 3.8 ± 0.4 4.0 ± 0.2 0.75
hs-CRP (mg/l) 2.9 ± 0.5 2.3 ± 0.8 2.7 ± 0.5 0.08
All values are mean (estimated marginal means based on baseline values as covariate in general linear model) ± SE.
aCalculated by using a general linear model with after treatment values as dependent variables, baseline values as covariates and treatment group as a
fixed factor.
bSignificantly different from STT groups (Bonferroni pairwise comparison was used; P < 0.05).
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improve blood pressure especially in hypertensive patients
[15]. The hypotensive effect of broccoli sprouts is also
controversial; supplementation of spontaneously hyper-
tensive stroke-prone rat with broccoli sprouts significantly
decreased blood pressure [16], while ingestion of broccoli
sprouts had not significant effect on blood pressure and
endothelial function measured by flow mediated dilation
in hypertensive patients [17]. The antioxidative and anti-
inflammatory property of sulforaphane in broccoli sprouts
have been proposed as a main mechanism contributing to
improvement of endothelial function and blood pressure.
The most interesting finding we observed one month
after the treatment was a significant increase in serum
triglyceride levels in patients with successfully eradicated
H.pylori who received standard triple therapy; while no
similar adverse effect was observed in patients who
were treated alternatively with BSP, or received BSP as
complementary treatment of standard triple therapy. Serum
triglycerides have been identified as major contributing
factor and independent predictor of coronary heart disease
in patients with type 2 diabetes, and lowering triglyceride
levels has always considered a main clinical target in
these patients [18]; it has been suggested that even a
temporary and short-term increase in triglyceride levels
could be accompanied by development of insulin resist-
ance, endothelial damage and dysfunction, especially in
patients with diabetes, via increased levels of intracellular
adhesion molecule-1, vascular cell adhesion molecule-1,
and E-selectin, as well as oxidative stress [19-21]. Another
important risk factor outcome observed following the H.
pylori eradication was clinically considerable, but not sta-
tistically significant, elevated triglyceride to HDL-C ratio
in the STT group; TG/HDL-C ratio is a main atherogenic
lipid parameter that is directly related to lipoproteinparticle size and especially small LDL-dense particles in
the plasma [22,23]; patients with type 2 diabetes with high
TG/HDL-C ratio are potentially at a higher risk for
increased arterial stiffness and atherosclerosis [24].
However the reason for the undesirable effects observed
of standard triple therapy following H.pylori eradication in
patients with type 2 diabetes is not clear, but the beneficial
effects of broccoli sprouts supplementation in improve-
ment of lipids and lipoproteins are well explained. The
potential effects of broccoli sprouts and its bioactive
components including isothiocyanate sulforaphane on
lipid and lipoprotein metabolism have previously been
investigated; phytonutrient compounds in broccoli sprouts
can bind with bile acids and reduce fat absorption, inhibit
lipoprotein lipase activity in adipose tissue, decrease
gene expression and the activity of key lipogenic enzymes,
including diacylglycerol acyltransferases, fatty acid synthase,
and acyl-CoA-cholesterol acyltransferase; moreover, indole
glucosinolates in broccoli sprouts reduce apolipoprotein B
secretion, which is a primary apolipoprotein of low-density
lipoproteins [25-27]. Human studies have also confirmed
the hypolipidemic effects of broccoli sprouts [28,29].
Increased serum levels of hs-CRP are considered as a
marker of H.pylori-induced inflammation in gastric
mucosa [30,31]; moreover sub-clinical inflammation and
increased level of hs-CRP have been identified as a main
contributor to development of insulin resistance and
diabetes complications, and also an independent risk
factor and powerful predictor of incident cardiovascular
events [32-34]. Current data are controversial in relation
to H.pylori eradication and improvement of inflammatory
parameters [35-38]. In our study, a significant decrease in
serum hs-CRP levels was observed only in patients
with successfully eradicated H.pylori treated with broccoli
sprouts powder per se, while hs-CRP levels remained
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properties of broccoli sprouts are mainly attributed to
sulforaphane which could inhibit cytokine production
through the activation of nuclear factor (erythroid-derived
2)-like-2 pathway and induction of NAD(P)H:quinon
oxidoreductase 1, an antioxidant phase II protein [39]; SFN
also inhibits production of inflammatory mediators and
cytokines including tumor necrosis factor-α, interlukine-6,
interlukine-1β, and prostaglandins through inhibition
of nuclear factor-κB transcriptional activity, as a key
modulator of pro-inflammatory processes [40,41].
To the best of our knowledge, this clinical trial was the
first study investigating comparative effects of broccoli
sprouts powder and standard triple therapy on H.pylori
infection and cardiovascular risk factor outcomes following
the H.pylori eradication in patients with type 2 diabetes.
The dose and duration of BSP treatment used in this study
were limited and therefore determination of optimum dose
and duration were not possible. Last, but not least, our
study was not adequately powered to explore possible
differences between groups in term of eradication rate.
Moreover, as expected because of a small sample size our
power was inadequate for subgroup analysis. Further
studies on the current topic are therefore recommended.
In conclusion, the study showed that standard triple
therapy could increase serum triglycerides and TG/HDL-C
ratio, as main cardiovascular risk factors, following H.pylori
eradication in patients with type 2 diabetes; while
broccoli sprouts powder, in addition to considerable
effect on H.pylori eradication and related inflammation,
could reduce the unfavorable effects of STT. Returning to
the hypothesis posted at the beginning of the study, it is
now possible to state that potential undesirable outcomes,
including cardiovascular risk factors especially in patients
with type 2 diabetes, during common medications used
for H.pylori eradication should be considered. Moreover,
use of natural antibacterial agents, including nutraceuti-
cals and functional ingredients such as broccoli sprouts,
beyond improving the efficacy of common treatment of H.
pylori infection, may attenuate undesirable side effects,
and consequently lead to health promoting outcomes in
the patients.
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